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Late events and side effects are reported in 392 children cured 
of leukemia. They originated from 1193 consecutively newly 
diagnosed children between 1972 and 1982, in first continuous 
complete remission for at least 6 y after diagnosis, and were 
treated according to Dutch Childhood Leukemia Study Group 
protocols (70%) or institutional protocols (30%), all including 
cranial irradiation for CNS prophylaxis. Data on late events 
(relapses, death in complete remission, and second malignancies) 
were collected prospectively after treatment; late side effects 
were retrospectively collected by a questionnaire, completed by 
the responsible pediatrician. The event-free survival of the 6-y 
survivors at 15 y after diagnosis was 92% (±2%). Eight late 
relapses and nine second malignancies were diagnosed, two 
children died in first complete remission of late toxicity of 
treatment, and one child died in a car accident. The most 
important long-term side effects reported were learning disabil­
ities (50%), short stature, obesity, and delayed pubertal develop­
ment. No increase in the incidence of cardiovascular, pulmonary,
urogenital, or gastrointestinal tract diseases or an increased vul­
nerability of the musculoskeletal system was found. However, 
prolonged follow-up is necessary to study the full-scale late 
effects of cytostatic treatment and radiotherapy administered 
during childhood. (Pedlatr Res 38: 802-807, 1995)
Abbreviations
ALL, acute lymphocytic leukemia 
ANLL, acute nonlymphocytic leukemia 
CCR, continuous first complete remission 
DCLSG, Dutch Childhood Leukemia Study Group 
EFS, event free survival 
HR, high risk
MDS, myelodysplastic syndrome 
NHR, nonhigh risk 
SDS, SD score 
WBC, white blood ceil count
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Cure is the aim of treatment of children and adolescents with 
leukemia. In general, children with leukemia who have been in 
CCR for at least 4 y after cessation of therapy, Le. 6 y after 
diagnosis, are considered to be cured (1). Over the past 20 y the 
cure rate for children with ALL has increased from 5-10% in 
the late sixties to 40-50%  in the seventies and 70-80%  in the 
eighties and early nineties (2). The outlook for children with 
ANLL is less favorable: only 35-40%  of the patients can 
expect cure with the current treatment strategies (3, 4).
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It has become increasingly apparent that the treatment to 
eradicate the leukemia has adverse long-term side effects. 
These late side effects consist of organ toxicity, disturbances in 
growth, pubertal and fertility development, psychosocial prob­
lems, immunosuppression, and infections. Furthermore, chil­
dren with cancer are at higher risk for the occurrence of second 
tumors.
Since 1972 virtually all newly diagnosed children with 
leukemia in The Netherlands are registered by the DCLSG. 
The DCLSG provides protocols for treatment and disposes of 
a Central Office for data management ancl analysis of treatment 
results and a Laboratory for confirmation of the diagnosis, 
immunophenotyping, and classification of the leukemia as well 
as for follow-up by examination of routine bone marrow and 
peripheral blood during treatment and after cessation of 
therapy.
Here we report the results of the DCLSG study on late 
events and long-term side effects in 392 survivors out of 1193
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consecutively newly diagnosed children with leukemia (age
0-15 y) in the period 1972-1982, treated with chemotherapy 
and radiotherapy (cranial irradiation).
METHODS
Patients. Patients registered by the DCLSG at diagnosis and 
in first CCR for at least 6 y at January 1,1988, were eligible for 
the study.
Treatment From 1972 to 1975 all ALL patients were treated 
according to the DCLSG protocols I and II, respectively. After 
1975 ALL patients were stratified into two risk groups: ALL- 
NHR constituting 70% of all ALL patients, and ALL-HR, 30% 
of the patients. ALL-NHR was defined as: initial WBC <50 X  
109/L, no mediastinal mass, no initial CNS involvement All 
other patients were ALL-HR patients. Children with ALL- 
NHR were treated according to the DCLSG protocols ALL III 
and ALL V, respectively, children with ALL-HR according to 
institutional protocols.
Until 1980, children with ANLL were also treated according 
to institutional protocols, thereafter until 1982 according to the 
DCLSG protocol ANLL 80. The treatment schemes and results 
of these DCLSG protocols have been published elsewhere 
(5-9).
Late events. Registration forms with treatment documenta­
tion, data on remission and survival status and, this being the 
case, on the occurrence of a second tumor, were completed for 
all patients by the responsible pediatrician regularly during and 
after cessation of therapy and sent to the Central Office* Blood 
and bone marrow slides for central examination were also sent 
to the Central Office.
EFS was defined as the time from diagnosis to relapse, death 
in remission, or the occurrence of a second tumor. The EFS 
curve was calculated according to the Kaplan-Meier method 
(10). Relapse was defined as >20-25%  blasts in the bone 
marrow and/or blast cells in the peripheral blood and/or CNS 
involvement and/or leukemic infiltration elsewhere. Bone mar­
row and/or CNS relapses as well as second hematologic ma­
lignancies had to be confirmed by the DCLSG laboratory.
Late side effects. Data on late side effects were retrospec­
tively collected in 1989-1990 by a questionnaire to be com­
pleted by the responsible pediatrician. This questionnaire con­
tained items concerning organ dysfunction (heart, liver, lungs, 
CNS, skin, gastrointestinal tract, eyes, musculoskeletal sys­
tem), severe or chronic diseases (hypertension, endocrine dis­
orders, chronic infections), height, weight, pubertal develop­
ment and fertility, school performance (the highest level thus 
far achieved), psychosocial status, employment, and insur­
ances. No specific psychometric tests were performed. As far 
as possible population-based normal data and figures were used 
for comparison (11, 12).
RESULTS 
Patients
Three hundred and ninety-two ex-patients were eligible for 
the study and available for calculation of EFS. The question­
naire on late side effects was completed for 273 (70%) ex­
patients. Patient characteristics are summarized in Table 1.
Late Events
Late events were evaluated as of January 1, 1994. The EFS 
of the 392 children in longstanding CCR is 92% (SE ± 2%) at 
15 y after diagnosis (Fig. 1). Eight patients relapsed, in nine 
patients second malignancies occurred, and three patients died 
in CCR (Table 2). The estimated cumulative proportion of late 
relapses and second malignancies 15 y after diagnosis is 3.2 
and 3.6%, respectively.
In 5 children the second malignancy developed in the area 
irradiated for CNS prophylaxis. One of the patients had also 
been treated with cyclophosphamide. The secondary AML and 
MDS occurred after treatment with doxorubicin and were 
associated with abnormalities of chromosome 11.
Three ex-patients died in CCR: one patient died of preexis­
tent hepatitis which progressed to liver cirrhosis, one patient 
died after 6 y of coma caused by a cerebral abscess as a 
consequence of otitis media during cytostatic treatment, and 
one patient died in a traffic accident. In four patients a histo­
logically benign tumor was diagnosed (Table 2),
Table I. Patients' characteristics
Eligible 
(/I =  392)
Questionnaire completed 
(fi =  273)
Type of leukemia
ALL 374 263
ANLL 6 4
AUL 12 6
Year of diagnosis
1972-1975 95 57
1976-1978 94 73
1979-1982 203 143
Treatment protocol (era)
ALL I (1972-1973) 3 1
ALL II (1973-1975) 73 43
ALL III (1975-1978) 78 56
ALL V (1979-1984) 173 128
ANLL 80 (1980-1982) 2 1
Institutional
ALL (high risk) 52 38
ANLL 10 5
AUL 1 1
Sex
Boys 190 136
Girls 202 137
Age at diagnosis (y)
< 2 47 36
2-10 294 206
> 1 0 51 31
Age at late effects study (y)
6 -1 0 27* 23
11-18 250* 192
19 -2 9 115* 58
Years after cessation of  
therapy
5-9 66 45
1 0 -1 4 326 228
* At December 31, 1989.
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Height in cm s.
Years from diagnosis
Figure 1. Event-free survival of 392 ex-patients with childhood acute leuke 
mia in first continuous complete remission for s 6  y.
Table 2. Late events in 392 ex-patients with childhood acute
leukemia (diagnosis 1972—1982)
Relapses Patients
Years after 
diagnosis
Bone marrow 3 7, 7 ,7
CNS 3 7, 8 ,11
Testis 1 8
Bone marrow +  CNS 1 8
Second tumors Patients Years after 
diagnosis
In area o f  cranial 
irradiation
Malignant
Astrocytoma 2 8 ,1 2 Yes
Basocellular carcinoma 3 7, 7 ,1 2 Yes
M. Hodgkin 1 7 Not relevant
Non-Hodgkin lymphoma 1 12 Not relevant
ANLL 1 15 Not relevant
MDS 1 9 Not relevant
Benign
Ovarian cyst 1 11 No
Angioleiomyoma 1 3 No
Multinodular struma 1 13 No
Bilateral meningioma 1 20 Yes
Death in CR Patients Years after 
diagnosis
Preexistent hepatitis 1 13
Infection 1 6
Traffic accident 1 9
Height in cms.
Figure 2. (A) Height and weight in 136 male patients with childhood acute 
leukemia in first continuous complete remission for > 6  y. (B) Height and 
weight in 137 female patients with childhood acute leukemia in first continu­
ous complete remission for ^ 6y ; pop =  population.
the final height was below the median height of the Dutch 
population: 173 cm versus 182 for male patients, 163 versus 
169 for female patients.
Pubertal development; progeny . Pubertal development 
started in due time in boys and girls, but progression was 
slower than in the average Dutch population in ex-patients 
known to be in the range of development P (pubic hair), G 
(genital development), or M (breast development) 2-5 (Table 
3). The median age of the menarche in ex-patients, 12 y (range 
10-14 y), was younger than in the average Dutch population: 
13 y (range 11-14 y) (11).
Nine infants were bom: eight to female ex-patients, and one 
male ex-patient fathered a child, All babies were well and 
healthy.
Organ toxicity. Organ toxicity was most frequently reported 
for the CNS and the skin (Table 4). Late cardiovascular, 
y after treatment the mean height SDS of both boys and girls pulmonary, urogenital, gastrointestinal, hepatic, and musculo-
Late Side Effects
Growth. For each patient the height SDS was calculated, 
defined as the patients' height minus the mean for the pertain­
ing age and sex, divided by the SD for that age. At diagnosis 
the mean height SDS of the patients was normal. However, ^ 4
was 1 SD lower than for the Dutch population. skeletal toxicity was rarely reported. The overall immunity, as
The height of the ex-patients was within the normal range of measured by the incidence of severe infections, seems to be 
the Dutch population; however, height and weight curves normal in leukemia patients off therapy.
showed a considerable number of ex-patients who were over- Psychosocial development A considerable part of the ex-
weight (Fig. 2, A and B). Both for male and female ex-patients patients (51%) had experienced learning problems. In the
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Table 3. Pubertal development in ex-patients with childhood acute
leukemia
Dutch population Ex-patients
P50 (y) (P10-P90) (in) P50 (y) (P10-P  90)
Boys
Pubic hair
P 2 11.7 (9-13.5) 11 12.5 (11.6-15.2)
P 3 13.1 (11.7-14.5) 17 14.6 (13.2-15.9)
P 4 13.9 (12.9-15.5) 16 16.7 (14.1-19.2)
P 5 15.0 (13.5-18.4) 38 19.1 (15.7-23.9)
Genital development
G 2 11.3 (9.3-13.3) 15 12.9 (11.6-15.2)
G 3 13.1 (11.6-14.5) 13 14.4 (13.2-15.9)
G 4 14.0 (12.8-15.6) 20 17.4 (14.4-21.5)
G 5 15.3 (13.5-18.6) 43 18.6 (15.2-23.1)
Girls 
Pubic hair
P 2 10.8 (9.0-12.6) 12 11.3 (10.3-13.0)
P 3 11.7 (10.2-13.1) 20 12.7 (11,3-17.2)
P 4 12.6 (11.3-14.0) 37 16.8 (12.1-20.5)
P 5 14.0 (12.2-16.4) 45 17.3 (13.9-25.1)
Breast development
M 2 10.5 (9.1-12.3) 12 11.8 (10.5-12.9)
M 3 11.7 (10.2-13.1) 22 12.7 (11.3-18.0)
M 4 12.9 (11.4-14.5) 33 16.8 (12.0-20.3)
M 5 14.2 (12.5 ) 51 17.2 (13,9-24.8)
Menarche 13.3 (11.7-14.9) 107 12 (10-14)
questionnaire the highest level of education thus far achieved 
had to be reported. Although many ex-patients were still too 
young to have reached their final educational level, it was 
apparent that a large proportion of ex-patients (12%) was 
unable to follow normal elementary or secondary school and 
had to be referred to special schools for children with learning 
defects. In the average Dutch population only 4% of the 
children have to be referred (12). There was a significant 
correlation between CNS irradiation at younger age and the 
occurrence of school problems (x1 p  = 0.002).
Fifty-five ex-patients had terminated their education and 
training, 27 of these had a full-time job, 13 a parttime job, and 
5 were unemployed. Five ex-patients were housewives with 
children. Of five ex-patients the occupational status was not 
reported.
Medical examinations and insurances. Twenty-nine (52%) 
out of 55 medically examined ex-patients were rejected as 
unfit; 26 men for entry into military service, one woman for 
nurses training because of short stature, and two ex-patient for 
reasons unknown.
Five (3%) out of 171 ex-patients who applied for an insur­
ance, were refused: two for health insurance, two for funeral 
insurance, and one for an unspecified insurance.
DISCUSSION
In this study 20 of 392 acute leukemia patients, considered 
to be cured, suffered from a life-threatening event. The rate of
Table 4. Late side effects in 273 ex-patients with childhood acute
leukemia (diagnosis 1972-1982)
Ex-patients
Central nervous system 
Learning disabilities 
Mental retardation 
Epilepsy
Growth hormone deficiency 
Skin/hair 
Thin hair/alopecia 
Melanocytic nevi (moles) 
Dysplastic nevi 
Vitiligo 
Peripheral nervous system 
Skeleton/teeth 
Osteoporosis 
M. Osgood Schlatter 
Dental root anomalies 
Dental caries 
Eyes 
Loss of vision 
Iridocyclitis*
Ears
Deafness
Hematological
Thrombocytopenia
Anemia
Liver
Kidneys
Gastrointestinal tract 
Severe infections 
Meningitis
Recurrent otitis media 
Heart 
Lungs 
Accidents
129
4
4 (52%)
5
28 (10%) 
13 (4.7%) 
2 
1 
4
3
2
2
6
3
2
3
1
1
1
1
1
5
13
* After herpes infection during treatment.
sis, reported by the Children’s Cancer Study Group, represent­
ing a 7-fold excess of all cancers. In the Children’s Cancer 
Study Group study, 24 (56%) out of 43 second malignancies 
occurred in the CNS, all in children who had been treated with 
cranial irradiation; however, no basocellular carcinomas were 
mentioned (13).
Therapy-related MDS and acute myeloid leukemia have 
been described in children in relation to previous treatment for 
solid tumors or acute lymphoblastic leukemia with drugs re­
acting either directly at DNA, such as the alkylating agents, or 
indirectly by targeting at DNA-topoisomerase II, such as the 
epipodophyllotoxins, anthracyclines, and actinomycin D. 
These second malignancies were associated with characteristic 
abnormalities of chromosomes 5 and/or 7 after alkylating 
agents, and of chromosome 1 lq23 after DNA topoisomerase II 
targeting drugs (14—16), In this survey two cases of secondary 
MDS and ANNL were identified. Both patients had been 
treated with doxorubicin.
The data collected by the questionnaire do not suggest an
late relapses in this nationwide, multi-institutional study is increase in the incidence of cardiovascular, pulmonary, uro-
slighily higher than observed in the single institution studies of genital, or gastrointestinal tract diseases, or an increased vul-
St. Jude Children’s Research Hospital in the same era (2). The nerability of the musculoskeletal system. The overall immu-
rate of second malignancies is in the same range as the nity, as measured by the incidence of severe infections, is
estimated cumulative proportion of 2.53%, 15 y after diagno- normal in ex-patients. No diabetes mellitus has been observed.
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Organ toxicity was most outspoken in the CNS. Although 
effective in preventing CNS relapse, it has become increasingly 
clear that cranial irradiation may cause neurotoxicity leading to 
severe learning disabilities (17). This was also observed in this 
study, as well as the fact that younger age at cranial irradiation 
is associated with more school and learning defects (18). These 
school problems are largely caused by verbal and attention 
deficits (19, 20). A recent study has shown an on-going decline 
in full-scale intelligence quotient after 18-24 Gy irradiation 
with the length of time from diagnosis (21).
Short stature in ex-leukemia patients may be caused by a 
combination of factors, such as growth hormone deficiency and 
the development of precocious puberty after cranial irradiation, 
and the longstanding administration of corticosteroids (22, 23). 
In a recent study, disproportionate short stature was established 
suggesting also a direct effect of chemotherapy on the spinal 
cartilage growth plates (24).
The occurrence of obesity in a high number of patients is 
still unexplained. Partial growth hormone deficiency by cranial 
irradiation, little exercise, high caloric intake, metabolic 
changes by long-term corticosteroid administration, or a 
change in body composition (25) may all be factors that play a 
role, but this phenomenon still needs further investigation.
Cranial irradiation has been related to precocious puberty. 
However, in our study, the median ages of the consecutive 
pubertal stages were higher than for the average Dutch popu­
lation, indicating a delay in pubertal development, notwith­
standing early menarche in some girls. This may be associated 
with gonadal toxicity of the administered chemotherapy (26). 
In a British study, testicular function after treatment for ALL, 
including cranial irradiation, was assessed by wedge biopsy at 
cessation of therapy and subsequently by clinical and biochem­
ical examination, and if possible semen analysis, 10 y later. At 
cessation of therapy moderate to severe testicular damage was 
found in the majority of the boys; 10 y later testicular function 
had recovered completely in all but half of a small number of 
patients with severe damage at cessation of therapy, indicating 
that in general the outlook for male fertility in ex-leukemia 
patients may be considered as good (27). The same investiga­
tors assessed that the long-term outlook for ovarian function in 
girls, treated with chemotherapy without cyclophosphamide or 
spinal or abdominal irradiation, was also good for most of the 
patients (28). However, these studies need further confirma­
tion.
The offspring of the ex-patients in the current study is 
normal. No increase in the incidence of congenital malforma­
tions or malignancies in children from ex-leukemia patients has 
been reported thus far (29, 30).
The administration of anthracyclines has been associated 
with cardiomyopathy in a dose-related fashion (cumulative 
dose: >300 mg/m2) (31). It is of interest that in this study no 
clinical signs of cardiomyopathy were reported in 73 ALL 
patients treated with daunorubicin (cumulative dose 100 mg/ 
m2) during induction treatment in study ALL V (7). This phase 
III study on the effectiveness of daunorubicin also offers an 
unique opportunity to study any late cardiac effects of low dose 
anthracycline in a comparative way. Such a study is now 
underway.
It has been shown that cytostatic treatment is associated with 
an increase in melanocytic nevi (moles), a strong risk factor for 
melanoma, in long term cancer survivors (32). However, thus 
far no increase in the incidence of melanoma in long term 
cancer survivors has been reported (33).
Shortening of dental roots has been observed after the 
administration of combination chemotherapy to young children 
(34). Preliminary study results suggest a relation with certain 
cytostatic drugs, rather than age at diagnosis for the develop­
ment of these abnormalities (35).
This survey confirms the data in the literature that prophy­
lactic cranial irradiation is a very important factor for the 
long-term impairment of the quality of life of children success­
fully treated for leukemia (17-21). In The Netherlands, since 
1984, prophylactic cranial irradiation has effectively been sub­
stituted by intensive systemic and intrathecal chemotherapy. 
Furthermore, it was shown in the ALL VI study that excellent 
results can be achieved in 70% of ALL patients without the 
administration of alkylating agents or anthracyclins (36).
This survey also confirms that the majority of leukemia 
patients in CCR 4 y after cessation of therapy has been cured; 
with current more effective treatment strategies the final cure 
rate may still further improve. Children cured of leukemia 
should have the same opportunities for education, employ­
ment, and insurances as their contemporaries who never had 
leukemia.
It is wrong to consider cured individuals as patients still 
suffering with the disease and to reject them for this reason to 
enter the uniformed services. Job and insurance discrimination 
in leukemia survivors should be prohibited by law, as for 
example has been realized in the United States by the passage 
of the Americans With Disabilities Act (37).
However, because many of the long-term effects of treat­
ment are still unknown, the importance of long-term follow-up 
of survivors of leukemia has to be stressed. The recommenda­
tions of the American Cancer Society Workshop on Adoles­
cents and Young Adults with Cancer (38-41) could be adapted 
to national or local circumstances.
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